Literature DB >> 29175651

Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis.

Lorena Airaghi1, Mario Rango2, Diletta Maira3, Valentina Barbieri2, Luca Valenti3, Rosa Lombardi3, Pietro Biondetti4, Silvia Fargion3, Anna Ludovica Fracanzani3.   

Abstract

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease is recognized not only as part of the metabolic syndrome but also as an independent predictor of cardiovascular disease.
METHODS: In this study, NMR spectroscopy method, together with perfusion techniques, was used to detect subclinical brain vascular damage in subjects with NAFLD without overt atherosclerosis risk factors (i.e. hypertension, diabetes, hypercholesterolemia, obesity).
RESULTS: The results suggest that subjects with histologically proven NAFLD have a reduced cerebral perfusion (CBFr) confined to limited brain areas, i.e., left semioval center and posterior cingulate cortex. No statistically significant differences in CBFr values were found, dividing the NAFLD cohort into subgroups, considering NAS score, presence/absence of NASH/fibrosis, and degree of steatosis.
CONCLUSIONS: Our data suggest that NAFLD per se may be involved in cerebral atherosclerotic disease. It will be interesting to draw longitudinal studies to determine whether these changes could evolve in more serious cerebral injury.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cerebral blood flow; Cerebrovascular disease; Magnetic resonance spectroscopy (MRS); Metabolic syndrome; Non-alcoholic fatty liver disease (NAFLD)

Mesh:

Year:  2017        PMID: 29175651     DOI: 10.1016/j.atherosclerosis.2017.11.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study.

Authors:  Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-23       Impact factor: 11.382

2.  Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence.

Authors:  Anne Catrine Daugaard Mikkelsen; Kristoffer Kjærgaard; Rajeshwar Prosad Mookerjee; Hendrik Vilstrup; Gregers Wegener; Cecilie Bay-Richter; Karen Louise Thomsen
Journal:  Neurochem Res       Date:  2022-03-01       Impact factor: 3.996

Review 3.  Fatty liver and cerebrovascular disease: plausible association and possible mechanisms.

Authors:  Sahil Khanna; Neal S Parikh; Lisa B VanWagner
Journal:  Curr Opin Lipidol       Date:  2022-02-01       Impact factor: 4.616

4.  A juvenile case with nonalcoholic steatohepatitis and traditional Korean medicine-based treatment.

Authors:  Chang-Gue Son
Journal:  Integr Med Res       Date:  2018-02-02

Review 5.  Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives.

Authors:  Kristoffer Kjærgaard; Anne Catrine Daugaard Mikkelsen; Charlotte Wilhelmina Wernberg; Lea Ladegaard Grønkjær; Peter Lykke Eriksen; Malene Flensborg Damholdt; Rajeshwar Prosad Mookerjee; Hendrik Vilstrup; Mette Munk Lauridsen; Karen Louise Thomsen
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

Review 6.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.